AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
2min chapter
#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials
Breakpoints
Valgan Cycle of Your Isn't a Med That's Necessarily Easy to Access.
The efficacy held for all subgroups, including those receiving lymphocyte depleting induction. There were significantly more adverse events for patients treated with valgan cycle of your 37% developed leukemia versus 11.3% in the La Terma Vier arm. The neutropenia was 16.5% versus 2.7%. And two times as many patients ended up needing GCSF to treat this adverse event. I just, to me, these are absolutely practice changing data.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode